{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:17:05Z","timestamp":1791429425576,"version":"4.3.3"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006488","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005635","name":"Funda\u00e7\u00e3o Calouste Gulbenkian","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jhepr.2021.100415","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T02:48:05Z","timestamp":1639450085000},"page":"100415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inducers of the NF-\u03baB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in\u00a0vitro"],"prefix":"10.1016","volume":"4","author":[{"given":"Maud","family":"Michelet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Alfaiate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieux","family":"Chard\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Faure-Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-4442","authenticated-orcid":false,"given":"Tobias","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Flore","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rivoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Heikenw\u00e4lder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2007-8350","authenticated-orcid":false,"given":"Anna","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-3419","authenticated-orcid":false,"given":"David","family":"Durantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-7809","authenticated-orcid":false,"given":"Julie","family":"Lucifora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100415_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(82)90156-8","article-title":"Influence of delta infection on severity of hepatitis B","volume":"2","author":"Smedile","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100415_bib2","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0016-5085(84)80153-5","article-title":"Fulminant B viral hepatitis: role of delta agent","volume":"86","author":"Govindarajan","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100415_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","article-title":"Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study","volume":"18","author":"Buti","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2021.100415_bib4","doi-asserted-by":"crossref","first-page":"104812","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2021.100415_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0032-1323629","article-title":"Treatment of chronic delta hepatitis","volume":"32","author":"Yurdaydin","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48weeks in HDV-related compensated cirrhosis: a case report of 3 patients","volume":"71","author":"Loglio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100415_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib12","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic\u00a0delta\u00a0hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2021.100415_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100415_bib16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jhep.2015.06.022","article-title":"Expression and functionality of Toll- and RIG-like receptors in HepaRG cells","volume":"63","author":"Luangsay","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib17","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/onc.2010.260","article-title":"The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development","volume":"29","author":"Wolf","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.jhepr.2021.100415_bib18","doi-asserted-by":"crossref","first-page":"a016246","DOI":"10.1101\/cshperspect.a016246","article-title":"Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors","volume":"7","author":"Pandey","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jhepr.2021.100415_bib19","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100415_bib20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1128\/JVI.74.5.2255-2264.2000","article-title":"Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines","volume":"74","author":"McClary","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","article-title":"Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis","volume":"150","author":"Xia","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100415_bib22","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41598-018-23525-w","article-title":"Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes","volume":"8","author":"Lucifora","year":"2018","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2021.100415_bib23","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100415_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2021.100415_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib26","article-title":"IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome","volume":"10","author":"Palumbo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2021.100415_bib27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jhep.2012.05.004","article-title":"Role of Toll-like receptor 2 in the immune response against hepadnaviral infection","volume":"57","author":"Zhang","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib28","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100415_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","article-title":"HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes","volume":"136","author":"Alfaiate","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2021.100415_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-60761-688-7_3","article-title":"Isolation and culture of primary hepatocytes from resected human liver tissue","volume":"640","author":"Lecluyse","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhepr.2021.100415_bib31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhepr.2021.100415_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in\u00a0vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100415_bib33","doi-asserted-by":"crossref","first-page":"17589","DOI":"10.1038\/s41598-020-74613-9","article-title":"Caspase inhibition rescues F1Fo ATP synthase dysfunction-mediated dendritic spine elimination","volume":"10","author":"Chen","year":"2020","journal-title":"Scientific Rep"},{"key":"10.1016\/j.jhepr.2021.100415_bib34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2019.12.019","article-title":"A\u00a0dual role for hepatocyte-intrinsic canonical NF-kappaB signaling in virus control","volume":"72","author":"Namineni","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31902","article-title":"HIF1alpha-mediated RelB\/APOBEC3B downregulation allows Hepatitis B Virus persistence","author":"Riedl","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib36","article-title":"New insights into hepatitis D virus persistence: the role of interferon response and implications for upcoming novel therapies","author":"Zhang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib37","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/JVI.74.16.7375-7380.2000","article-title":"The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication","volume":"74","author":"Modahl","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/154.4.702","article-title":"Antigens of hepatitis delta virus in the liver and serum of humans and animals","volume":"154","author":"Bergmann","year":"1986","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/jvi.58.3.945-950.1986","article-title":"Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope","volume":"58","author":"Bonino","year":"1986","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1128\/jvi.64.3.1021-1027.1990","article-title":"A\u00a0specific base transition occurs on replicating hepatitis delta virus RNA","volume":"64","author":"Luo","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib41","first-page":"369A","article-title":"Mimicking Interferon-\u03b1 (IFN\u03b1) inhibitory activity on hep- atitis B virus (HBV) transcription and replication by tar- geting the epigenetic control of nuclear cccDNA minichromosome with epigenetic small molecules","volume":"56","author":"Belloni","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib42","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","article-title":"Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection","volume":"50","author":"Hosel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2013.11.010","article-title":"Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection","volume":"60","author":"Giersch","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib44","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib45","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1128\/jvi.64.10.5066-5069.1990","article-title":"Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication","volume":"64","author":"Chao","year":"1990","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib46","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1128\/jvi.66.11.6641-6648.1992","article-title":"Oligomerization of hepatitis delta antigen is required for both the trans-activating and trans-dominant inhibitory activities of the delta antigen","volume":"66","author":"Xia","year":"1992","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib47","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/jvi.65.5.2357-2361.1991","article-title":"trans-dominant inhibition of human hepatitis delta virus genome replication","volume":"65","author":"Glenn","year":"1991","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib48","doi-asserted-by":"crossref","first-page":"100354","DOI":"10.1016\/j.jhepr.2021.100354","article-title":"Control of APOBEC3B induction and cccDNA decay by NF-kappaB and miR-138-5p","volume":"3","author":"Faure-Dupuy","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2021.100415_bib49","first-page":"1","article-title":"Characterization of pattern recognition receptor expression and functionality in liver primary cells and derived cell lines","author":"Faure-Dupuy","year":"2018","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.jhepr.2021.100415_bib50","doi-asserted-by":"crossref","first-page":"118569","DOI":"10.1016\/j.ijpharm.2019.118569","article-title":"Molecular modelling of TLR agonist Pam3CSK4 entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality","volume":"568","author":"Lamrayah","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jhepr.2021.100415_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2016.06.018","article-title":"Polylactic acid (PLA) controlled delivery carriers for biomedical applications","volume":"107","author":"Tyler","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2021.100415_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","article-title":"A\u00a0lymphotoxin-driven pathway to hepatocellular carcinoma","volume":"16","author":"Haybaeck","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2021.100415_bib53","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1158\/0008-5472.CAN-06-0217","article-title":"Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy","volume":"66","author":"Lukashev","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2021.100415_bib54","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/infdis\/141.5.590","article-title":"Transmission of the hepatitis B virus-associated delta antigen to chimpanzees","volume":"141","author":"Rizzetto","year":"1980","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/hep.1840050404","article-title":"Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers","volume":"5","author":"Hadziyannis","year":"1985","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib56","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1128\/jvi.63.4.1612-1618.1989","article-title":"Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks","volume":"63","author":"Negro","year":"1989","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"Lutgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100415_bib58","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1128\/JVI.01609-10","article-title":"Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses","volume":"85","author":"Pollicino","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib59","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.aids.0000180787.10553.b2","article-title":"Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain","volume":"19","author":"Arribas","year":"2005","journal-title":"Aids"},{"key":"10.1016\/j.jhepr.2021.100415_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0168-8278(91)90911-T","article-title":"Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection","volume":"12","author":"Colombo","year":"1991","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100415_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/00365548709032395","article-title":"Hepatitis D virus (delta agent) superinfection in an endemic area of hepatitis B infection: immunopathologic and serologic findings","volume":"19","author":"Lee","year":"1987","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhepr.2021.100415_bib62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jmv.1890310408","article-title":"Hepatitis B virus clearance from serum and liver after acute hepatitis delta virus superinfection in chronic HBsAg carriers","volume":"31","author":"Pastore","year":"1990","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhepr.2021.100415_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01643238","article-title":"Interaction between HDV and HBV infection in HBsAg-chronic carriers","volume":"19","author":"Sagnelli","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.jhepr.2021.100415_bib64","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/jvh.12947","article-title":"Viral dominance patterns in chronic hepatitis delta determine early\u00a0response to interferon alpha therapy","volume":"25","author":"Lutterkort","year":"2018","journal-title":"J\u00a0Viral Hepat"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:36Z","timestamp":1762900056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2589555921001919"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100415","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inducers of the NF-\u03baB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in\u00a0vitro","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100415"}}